* Valsartan, an angiotensin II receptor blocker, is a safe and effective alternative for patients with heart failure who can't take angiotensin-converting enzyme (ACE) inhibitors, the standard treatment, according to a recent study.
The findings were the result of a subgroup analysis of the Valsartan Heart Failure Trial, which evaluated the effects of valsartan in patients with heart failure. The subgroup analysis looked at 366 patients who weren't receiving ACE inhibitors. In these patients, morbidity and mortality were reduced when compared with the placebo group. The patients on valsartan also had physiologic improvements in ejection fraction, left ventricular internal diameter in diastole, and plasma neurohormone levels.
Source: Maggioni, A., et al. (Valsartan Heart Failure Trial Investigators): "Effects of Valsartan on Morbidity and Mortality in Patients with Heart Failure Not Receiving Angiotensin-Converting Enzyme Inhibitors," Journal of the American College of Cardiology, October 16, 2002.
Copyright Springhouse Corporation Feb 2003
Provided by ProQuest Information and Learning Company. All rights Reserved
Contact
Home
A
Hydrocodone